End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 AUD | -11.76% | -11.76% | -25.00% |
Apr. 10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Feb. 29 | Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2024 * | 11.6M 7.59M | Sales 2025 * | 3.6M 2.35M | Capitalization | 17.91M 11.71M |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.23M | Net income 2025 * | -13M -8.5M | EV / Sales 2024 * | 0.92 x |
Net cash position 2024 * | 7.2M 4.71M | Net cash position 2025 * | 9.2M 6.02M | EV / Sales 2025 * | 2.42 x |
P/E ratio 2024 * |
-1.36
x | P/E ratio 2025 * |
-1.67
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.57% |
Latest transcript on Syntara Limited
1 day | -11.76% | ||
1 week | -11.76% | ||
Current month | -28.57% | ||
1 month | -28.57% | ||
3 months | -11.76% | ||
6 months | -54.55% | ||
Current year | -25.00% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 03-03-11 |
Director of Finance/CFO | 67 | 02-11-30 | |
Jana Baskar
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 03-03-11 |
Director of Finance/CFO | 67 | 02-11-30 | |
Kathleen Metters
CHM | Chairman | 66 | 17-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.015 | -11.76% | 1,777,263 |
24-04-26 | 0.017 | +6.25% | 4,541 |
24-04-24 | 0.016 | -5.88% | 5,793,995 |
24-04-23 | 0.017 | 0.00% | 1,711,394 |
End-of-day quote Australian S.E., April 28, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.00% | 13.24M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- SNT Stock